

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

ExpiCHO-S

RRID:CVCL_5J31

Type: Cell Line

Proper Citation

RRID:CVCL_5J31

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5J31

Proper Citation: RRID:CVCL_5J31

Description: Cell line ExpiCHO-S is a Spontaneously immortalized cell line with a species of origin Cricetulus griseus (Chinese hamster)

Sex: Female

Comments: Characteristics: Has been selected for high protein expression., Group: Serum/protein free medium cell line.

Category: Spontaneously immortalized cell line

Organism: Cricetulus griseus (Chinese hamster)

Name: ExpiCHO-S

Cross References: Wikidata:Q54833017

ID: CVCL_5J31

Hierarchy: cvcl_7183

Record Creation Time: 20220427T215840+0000

Record Last Update: 20260829T232626+0000

Ratings and Alerts

No rating or validation information has been found for ExpiCHO-S.

No alerts have been found for ExpiCHO-S.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 48 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kim Y, et al. (2026) Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells. *ACS nano*, 20(12), 9925.

Huang F, et al. (2026) Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer. *iScience*, 29(6), 115849.

Ochtrup P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. *Nature communications*, 17(1), 759.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1120.

McCaffrey KD, et al. (2026) Molecular basis for protection and cross-protection by human antibodies targeting the parainfluenza virus hemagglutinin-neuraminidase protein. *bioRxiv : the preprint server for biology*.

Hammoudi A, et al. (2026) Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses. *EBioMedicine*, 127, 106269.

Acciani M, et al. (2026) Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins. *Cell host & microbe*, 34(6), 1067.

Waki K, et al. (2025) Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein. *eLife*, 12.

Feng Z, et al. (2025) Structural and functional insights into the evolution of SARS-CoV-2 KP.3.1.1 spike protein. *Cell reports*, 44(7), 115941.

Rijal P, et al. (2025) Structure-guided loop grafting improves expression and stability of influenza neuraminidase for vaccine development. *eLife*, 14.

Kim B, et al. (2025) Development of recombinant Mesozumab-CPTin that dual-targets mesothelin and CP2c for anticancer therapy. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 193, 118799.

Schendel SL, et al. (2025) A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein. *Cell reports*, 44(4), 115499.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. *Cancer research communications*, 5(3), 476.

Selezneva EM, et al. (2025) Neprilysin 2 catalyses the degradation of natriuretic peptides despite sacubitrilat Inhibition. *Scientific reports*, 15(1), 27401.

Vogl AM, et al. (2025) TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile. *Molecular cancer therapeutics*, 24(11), 1685.

Puchol Tarazona AA, et al. (2024) Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer. *Molecular cancer therapeutics*, 23(9), 1219.

Zhang Y, et al. (2024) A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus. *eLife*, 12.

Johnson NV, et al. (2024) Discovery and characterization of a pan-betacoronavirus S2-binding antibody. *Structure (London, England : 1993)*, 32(11), 1893.

Cui L, et al. (2024) A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates. *iScience*, 27(7), 110208.

Wolters RM, et al. (2024) Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface. *Immunity*, 57(6), 1413.